CRNX Quote, Financials, Valuation and Earnings

Clearside Biomedical has a net margin of -18560.15% compared to Crinetics Pharmaceuticals's net margin of -740.66%. Crinetics Pharmaceuticals's return on equity of -42.43% beat Clearside Biomedical's return on equity of --.

Crinetics Pharmaceuticals has a consensus price target of $75.07, signalling upside risk potential of 40.32%. On the other hand Clearside Biomedical has an analysts' consensus of -- which suggests that it could grow by 587.84%. Given that Clearside Biomedical has higher upside potential than Crinetics Pharmaceuticals, analysts believe Clearside Biomedical is more attractive than Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals has a beta of 0.597, which suggesting that the stock is 40.297% less volatile than S&P 500. In comparison Clearside Biomedical has a beta of 2.292, suggesting its more volatile than the S&P 500 by 129.225%.

Crinetics Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clearside Biomedical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals pays -- of its earnings as a dividend. Clearside Biomedical pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals quarterly revenues are $399K, which are smaller than Clearside Biomedical quarterly revenues of $1M. Crinetics Pharmaceuticals's net income of -$76.8M is lower than Clearside Biomedical's net income of -$7.7M. Notably, Crinetics Pharmaceuticals's price-to-earnings ratio is -- while Clearside Biomedical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals is -- versus 7.98x for Clearside Biomedical. Usually stocks with elevated PS ratios are considered overvalued.

iBio has a net margin of -18560.15% compared to Crinetics Pharmaceuticals's net margin of -4444.57%. Crinetics Pharmaceuticals's return on equity of -42.43% beat iBio's return on equity of -148.3%.

Crinetics Pharmaceuticals has a consensus price target of $75.07, signalling upside risk potential of 40.32%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that iBio has higher upside potential than Crinetics Pharmaceuticals, analysts believe iBio is more attractive than Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals has a beta of 0.597, which suggesting that the stock is 40.297% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

Crinetics Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals quarterly revenues are $399K, which are larger than iBio quarterly revenues of $175K. Crinetics Pharmaceuticals's net income of -$76.8M is lower than iBio's net income of -$4M. Notably, Crinetics Pharmaceuticals's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -18560.15% compared to Crinetics Pharmaceuticals's net margin of -49.65%. Crinetics Pharmaceuticals's return on equity of -42.43% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Crinetics Pharmaceuticals has a consensus price target of $75.07, signalling upside risk potential of 40.32%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Crinetics Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals has a beta of 0.597, which suggesting that the stock is 40.297% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Crinetics Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals quarterly revenues are $399K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Crinetics Pharmaceuticals's net income of -$76.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Crinetics Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -18560.15% compared to Crinetics Pharmaceuticals's net margin of -2357.27%. Crinetics Pharmaceuticals's return on equity of -42.43% beat Palatin Technologies's return on equity of --.

Crinetics Pharmaceuticals has a consensus price target of $75.07, signalling upside risk potential of 40.32%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Crinetics Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals has a beta of 0.597, which suggesting that the stock is 40.297% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Crinetics Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals quarterly revenues are $399K, which are larger than Palatin Technologies quarterly revenues of $350K. Crinetics Pharmaceuticals's net income of -$76.8M is lower than Palatin Technologies's net income of -$7.8M. Notably, Crinetics Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.